Reset Therapeutics

Our Leadership

Founded in 2008 by leaders in the field of molecular clock biology and Bay City Capital, the company has unparalleled expertise and intellectual property related to molecular clocks and the roles that they play in health and disease.

Our Leadership

Executive Team

Ross Bersot, CFA
President and CEO

Ross Bersot, CFA

President and CEO

Ross Bersot, CFA is the President and CEO of Reset Therapeutics.  Mr. Bersot founded Reset Therapeutics in 2008 with Dr. Ronald Evans (Salk Institute) and Drs. Joseph Takahashi and Masashi Yanagisawa (University of Texas Southwestern Medical Center).

Previously, Mr. Bersot was a Managing Director of Bay City Capital, where he focused on investment opportunities in visionary biopharmaceutical and enabling technology companies. He is a member of the board of directors of Reset Therapeutics and an observer on the board of Epizyme, Inc. Mr. Bersot also serves on the board of directors of Wild4Life, a nonprofit that provides essential health services to rural communities in remote areas of Zimbabwe and other African nations via partnerships with local employers and government-related organizations. He is also the Regional Chairman of the Northern California Volunteer Committee for the UCLA Fund Chancellor’s Society. Mr. Bersot received a B.A. in Economics from the University of California, Los Angeles.

Paul Humphries, Ph.D.
Head of Drug Discovery

Paul Humphries, Ph.D.

Head of Drug Discovery

Dr. Humphries is the Head of Drug Discovery at Reset Therapeutics. Previously, he was a Senior Principal Scientist at Pfizer working in the area of Metabolic Diseases. While at Pfizer, Dr. Humphries worked on programs resulting in seven Investigational New Drug (IND) submissions to the U.S. Food and Drug Administration across four late stage projects. He was also responsible for numerous go/no go decisions on early stage projects. Dr. Humphries has authored more than 25 scientific articles and patents on a wide range of topics/drug targets and received the Pfizer Global R&D Achievement Award in 2005.

Over the course of his Pfizer career, Dr. Humphries led or was a member of many successful project teams. These teams were instrumental in the discovery and development of investigational molecules with potential utility in the treatment of cancer, diabetes, metabolic syndrome, and osteoporosis. He received his Ph.D. from the University of Sheffield in the UK and performed postdoctoral research at Florida State University.

Shu Kurosaki, CPA
Vice President, Finance & Administration

Shu Kurosaki, CPA

Vice President, Finance & Administration

Mr. Kurosaki is the Vice President, Finance & Administration at Reset Therapeutics. Previously, he was the Vice President, Finance & Administration at MacuSight, a developer for the treatment of serious ocular diseases. While at MacuSight, Mr. Kurosaki managed the financial and general operational aspects of the Company and played a key financial role in a license collaboration agreement with a publicly traded ophthalmology company. Prior to MacuSight, Mr. Kurosaki served as Director of Finance at Oculex Pharmaceuticals, which was acquired by Allergan in 2003 and ultimately marketed Ozurdex®, a biodegradable implant that has received regulatory approval in the US and abroad. Mr. Kurosaki also served as an audit manager at PricewaterhouseCoopers and is an active Certified Public Accountant in California. Mr. Kurosaki received his B.S. in Business Administration from the University of California at Berkeley.

Board

Ross Bersot, CFA

Ross Bersot, CFA

President and CEO

Ross Bersot, CFA is the President and CEO of Reset Therapeutics.  Mr. Bersot founded Reset Therapeutics in 2008 with Dr. Ronald Evans (Salk Institute) and Drs. Joseph Takahashi and Masashi Yanagisawa (University of Texas Southwestern Medical Center).

Previously, Mr. Bersot was a Managing Director of Bay City Capital, where he focused on investment opportunities in visionary biopharmaceutical and enabling technology companies. He is a member of the board of directors of Reset Therapeutics and an observer on the board of Epizyme, Inc. Mr. Bersot also serves on the board of directors of Wild4Life, a nonprofit that provides essential health services to rural communities in remote areas of Zimbabwe and other African nations via partnerships with local employers and government-related organizations. He is also the Regional Chairman of the Northern California Volunteer Committee for the UCLA Fund Chancellor’s Society. Mr. Bersot received a B.A. in Economics from the University of California, Los Angeles.

Fred Craves, Ph.D.

Fred Craves, Ph.D.

Founder and Managing Director, Bay City Capital

Fred Craves, Ph.D., is the Founder and a Managing Director of Bay City Capital. Before founding Bay City Capital, he spent over 20 years leading and managing biotechnology and pharmaceutical companies. Previously, he was Executive Vice President of Schering Berlin and Chief Executive Officer and President of Berlex Biosciences, a research, development, and manufacturing organization. He founded Burrill & Craves, a merchant bank focused on biotechnology and emerging pharmaceutical companies. He was also the founding Chairman of the Board and Chief Executive Officer of Codon, and co-founder of Creative Biomolecules. Dr. Craves is a member of the boards of directors of Dermira, Encarta, Madrigal Pharmaceuticals, and Tallikut Pharmaceuticals. He also serves as a member of The J. David Gladstone Institutes’ Advisory Council and is a member of the Board of Trustees of Loyola Marymount University in Los Angeles. Dr. Craves earned a B.S. in Biology from Georgetown University and a Ph.D. in Pharmacology and Toxicology from the University of California, San Francisco.

Blair Jackson

Blair Jackson

Vice President, Alkermes, plc.

Blair Jackson is the Vice President of global business development at Alkermes, Inc., where he is responsible for all licensing, mergers and acquisitions and alliance management activity. Previously, Mr. Jackson served on the board of Civitas Therapeutics, which was acquired by Acorda Therapeutics. Mr. Jackson earned a Bachelor of Arts degree in biochemistry from the University of Calgary, a Bachelor of Arts in chemical engineering and a Master of Business Administration from the University of Alberta, and a Master of Science in chemical engineering practice from the Massachusetts Institute of Technology.

Steve Kay, Ph.D.

Steve Kay, Ph.D.

PRESIDENT OF THE SCRIPPS RESEARCH INSTITUTE

Dr. Kay is the President of the Scripps Research Institute and Dean of the Dornsife College of Letters, Arts and Sciences at the University of Southern California.  Dr. Kay’s research involves the large-scale application of genomics technologies and systems approaches to understand complex regulatory networks in plant and animal cells. He has applied functional genomics screens and chemical biology approaches to elucidate the composition of the molecular circuitry underlying circadian rhythms. His group identified the first small molecule modulators of clock proteins. He has published over 200 papers and is named by the Institute for Scientific Information as a highly cited scientist. His recent interests lie at the interface between quantitative and experimental science, as well as continuing to apply high throughput technologies to the discovery of therapeutics.

Hoyoung Huh, M.D., Ph.D.

Hoyoung Huh, M.D., Ph.D.

Chairman of the Board of Geron and Cytomx Therapeutics

Hoyoung Huh, M.D., Ph.D., is the Chairman of the Board of Geron and Cytomx Therapeutics.  Dr. Huh also is Chairman of the Scientific Advisory Board and Director of AntriaBio. Additionally, Dr. Huh serves on the board of directors of several privately-held companies. Dr. Huh served as CEO of BiPar Sciences, which was acquired by Sanofi; Director of Facet Biotech acquired by Abbott; Director of Calibra Medical acquired by J&J; Chairman of Epizyme; Director of Addex Pharmaceuticals; Director of EOS acquired by Clovis Oncology; Director and COO of Nektar Therapeutics; and Director of Actogenix acquired by Intrexon. Dr. Huh formerly was a partner at McKinsey & Company and physician scientist at Cornell University Medical College and Sloan-Kettering Cancer Center. Dr. Huh holds an A.B. in biochemistry from Dartmouth College and an M.D. and Ph.D. in genetics and cell biology from Cornell University Medical College and Sloan-Kettering Institute.

Scientific Advisors

Joe Bass, M.D., Ph.D.

Joe Bass, M.D., Ph.D.

Professor of Medicine, Feinberg College of Medicine, Department of Neurobiology and Physiology, Northwestern University

Dr. Bass is a physician-scientist who is a Professor of Medicine in the Feinberg School of Medicine of Northwestern University, where he is Chief of the Division of Endocrinology, Metabolism and Molecular Medicine in addition to the Department of Neurobiology  at Northwestern University. He maintains clinical activity and training responsibilities within the Division of Endocrinology and Molecular Medicine at Northwestern. His research group at Northwestern has focused for over the past decade on the interconnections between circadian systems, sleep, bioenergetics and metabolism. His group was the first to establish a genetic link between clock disruption, obesity, and metabolic syndrome, and to define the role of clock genes in beta cell failure and diabetes. Their work has also established that dietary fat feeds back to disrupt the clock, a process that has implications for the interaction between sleep, rhythms disorders, and diabetes. His studies seek to translate basic principles of clock function to gain insight into endocrine physiology, with the goal of participating in the development of novel therapies for human diabetes and obesity.

Prior to his present position, Dr. Bass was Chief of Endocrinology at NorthShore University Hospital and served on the faculty of the University of Chicago. He has been active as a scientific advisor for both large pharmaceutical and biotech companies involved in the development of small molecule and biologic therapeutics for obesity and diabetes. Dr. Bass is a member of the Association of American Physicians and holds the Charles F. Kettering chair at Northwestern University.  He has been the recipient of fellowships from the Juvenile Diabetes Research Foundation and the Howard Hughes Medical Institute. Dr. Bass received both an M.D. and Ph.D. degree in biochemistry with a focus on lipid metabolism prior to completing his endocrinology training at the University of Chicago.

Ron Evans, Ph.D.

Ron Evans, Ph.D.

Professor, Molecular and Developmental Biology, Salk Institute

Dr. Evans is a professor in the Gene Expression Laboratory, a Howard Hughes Medical Institute Investigator and holds the March of Dimes Chair in Developmental and Molecular Biology at the Salk Institute.  He is an authority on hormones, both their normal activities and their roles in disease. His lab discovered a large family of molecules, named receptors, which respond to steroids, vitamin A, and thyroid hormones, helping to control sugar, salt, calcium, and fat metabolism. In addition to their impact on daily health, these receptors are targets in the treatment of breast cancer, prostate cancer, and leukemia, as well as osteoporosis and asthma. Dr. Evans’ studies also led to the discovery of a new hormone that controls the formation of fat. He also discovered a class of drugs known as “exercise mimetics,” which enhance running performance and promote fat burning even in the absence of exercise. These hormones and investigational drugs represent new potential treatments for obesity-related diseases such as type 2 diabetes.

Dr. Evans was the scientific founder of Ligand Pharmaceuticals, X-Ceptor Therapeutics (acquired by Exelixis in 2004), Syndax Pharmaceuticals and is an advisor to Epizyme and Aragon Pharmaceuticals. He has received numerous scientific awards and is a member of the National Academy of Sciences and the Institute of Medicine. He serves on the editorial boards of Cell, Cell Metabolism and Genes and Development. Dr. Evans received his Ph.D. in Microbiology and Immunology from the University of California, Los Angeles, and completed a postdoctoral fellowship at Rockefeller University.

Carla B. Green, Ph.D.

Carla B. Green, Ph.D.

Professor, Neuroscience, University of Texas Southwestern Medical Center

Dr. Green is a Professor and Distinguished Scholar of Neuroscience at the University of Texas Southwestern Medical Center in Dallas, Texas.  Her lab studies the molecular mechanism of the mammalian circadian clock and how it controls rhythmic physiology.   She originally identified the rhythmic gene Nocturnin and demonstrated that this gene encodes a deadenylase – a polyA-specific ribonuclease that removes the polyA tails from mRNAs – and showed that this protein contributes to the circadian gene expression patterns through post-transcriptional regulation of mRNA stability and translation.  Her studies of Nocturnin function have lead to the discovery that this protein is a key circadian regulator of lipid metabolism and uptake. Her lab continues to focus on Nocturnin and on other circadian post-transcriptional regulatory mechanisms, as well as studying more broadly the general role of the circadian clock in metabolism.  Dr. Green’s lab also works on the molecular mechanism of the central clock with an emphasis on the roles of the Cryptochrome proteins.

Before moving to UT Southwestern, Dr. Green was a Professor of Biology at the University of Virginia. She has received multiple awards, participated in several NIH and NSF study sections and advisory committees, chaired numerous scientific meetings, and Dr. Green’s lab also works on the molecular Editorial Board for the Journal of Biological Rhythms. Dr. Green received her Ph.D. and completed a postdoctoral fellowship in the Department of Biochemistry and Molecular Biology and the Department of Anatomy and Cell Biology, respectively, at the University of Kansas Medical Center.

John B. Hogenesch, Ph.D.

John B. Hogenesch, Ph.D.

Professor of Molecular and Cellular Physiology, University of Cincinnati College of Medicine

Dr. Hogenesch is the Ohio Eminent Scholar and Professor of Molecular and Cellular Physiology at the University of Cincinnati in Cincinnati, Ohio. His lab studies genome biology with a focus on the molecular mechanisms of circadian rhythms in mammals. Dr. Hogenesch discovered several new bHLH-PAS transcription factors, including the hypoxia inducible factors, as well as the core clock components, Npas2, Bmal2, Rora, and Bmal1, the only required component of the mammalian circadian clock. Dr. Hogenesch also pioneered the discovery of clock regulated gene expression in plants, flies, mice, and man. As a genome biologist, Dr. Hogenesch’s lab applies and integrates various disciplines including bioinformatics, genomics, molecular and cellular biology, and genetics.

Before moving to Cincinnati, Dr. Hogenesch was Professor and Vice Chair of Pharmacology at the University of Pennsylvania Perelman School of Medicine. He did his Ph.D. in Neuroscience at Northwestern University. Currently, Dr. Hogenesch is a Penn Fellow, sits or has sat on the Scientific Advisory Boards of Qiagen, Mimetics, Bio-Rad, the Ryan Licht Sang Foundation Medical Committee, and the Gene Ontology (GO) consortium, and is an advisor to several National Institutes of Health, NIDDK, NCI, NHLBI, and the Environmental Protection Agency (EPA).

Steve Kay, Ph.D.

Steve Kay, Ph.D.

PRESIDENT OF THE SCRIPPS RESEARCH INSTITUTE

Dr. Kay is the President of the Scripps Research Institute and Dean of the Dornsife College of Letters, Arts and Sciences at the University of Southern California.  Dr. Kay’s research involves the large-scale application of genomics technologies and systems approaches to understand complex regulatory networks in plant and animal cells. He has applied functional genomics screens and chemical biology approaches to elucidate the composition of the molecular circuitry underlying circadian rhythms. His group identified the first small molecule modulators of clock proteins. He has published over 200 papers and is named by the Institute for Scientific Information as a highly cited scientist. His recent interests lie at the interface between quantitative and experimental science, as well as continuing to apply high throughput technologies to the discovery of therapeutics.

David Mangelsdorf, Ph.D.

David Mangelsdorf, Ph.D.

Professor and Chair, Department of Pharmacology, University of Texas Southwestern Medical Center

Dr. Mangelsdorf is Professor and Chair of the Department of Pharmacology, a Professor in the Department of Biochemistry, and the Raymond and Ellen Willie Distinguished Chair in Molecular Neuropharmacology at the University of Texas Southwestern Medical Center. He also is an Investigator of the Howard Hughes Medical Institute. Dr. Mangelsdorf is interested in understanding the molecular basis of transcriptional signaling by nuclear hormone receptors and exploiting their ligand dependency to discover novel therapeutic options for fighting diseases such as atherosclerosis, gallstone disease, cholestasis, metabolic syndrome, cancer, and infectious parasitic diseases. His laboratory has made several important discoveries related to the ligands and receptors that regulate lipid metabolism and cholesterol.

Before his appointments to UT Southwestern, Dr. Mangelsdorf was a Staff Scientist in the Gene Expression Laboratory at the Salk Institute. He has served on the advisory boards of Ligand Pharmaceuticals, X-Ceptor Therapeutics, Exelixis, and Aragon Pharmaceuticals. He has received numerous awards and is a member of the National Academy of Sciences, and currently is an editorial board member of the Proceedings of the National Academy of Sciences and Cell Metabolism. Dr. Mangelsdorf received his Ph.D. in biochemistry from the University of Arizona and completed a postdoctoral fellowship at the Howard Hughes Medical Institute, Gene Expression Laboratory at the Salk Institute.

Joseph S. Takahashi, Ph.D.

Joseph S. Takahashi, Ph.D.

Chair, Department of Neuroscience, University of Texas Southwestern Medical Center

Dr. Takahashi is chair of the Department of Neuroscience and an Investigator in the Howard Hughes Medical Institute at the University of Texas Southwestern Medical Center in Dallas, Texas. He currently holds the Loyd B. Sands Distinguished Chair in Neuroscience. Dr. Takahashi has pioneered the use of forward genetics and positional cloning in the mouse as a tool for discovery of genes underlying neurobiology and behavior, and his discovery of the mouse and human clock genes led to a description of a conserved circadian clock mechanism in animals.

Before moving to UT Southwestern, Dr. Takahashi was the Walter and Mary Elizabeth Glass Professor in the Life Sciences at Northwestern University. In addition, he was also the director of the Center for Functional Genomics. He was a co-founder of Hypnion, Inc., a biotech discovery company in Worcester, Mass., that investigated sleep/wake neurobiology and pharmaceuticals (now owned by Eli Lilly and Co.) He has received numerous awards, including election to the National Academy of Sciences, the American Academy of Arts and Sciences and has served on a number of NIH advisory committees. Dr. Takahashi also has served on the scientific advisory boards for Eli Lilly and Company, the Genomics Research Institute for the Novartis Foundation, The Klingenstein Fund, the Searle Scholars Foundation, the McKnight Foundation, the Allen Institute for Brain Science, the Max Planck Institute for Biophysical Chemistry, the Bristol-Myers Squibb Neuroscience Award Selection Committee, and the Restless Legs Syndrome Foundation. He is or was a member of the editorial boards for PNAS, PLoS Genetics, Curr. Opin. Neurobiol., J. Biol. Rhythms, Genes Brain Behav., Neuron, Physiol. Genomics and the Faculty of 1000. Dr. Takahashi received a Ph.D. in neuroscience from the University of Oregon, Eugene and completed a postdoctoral fellowship at the National Institute of Mental Health.

Masashi Yanagisawa, M.D., Ph.D.

Masashi Yanagisawa, M.D., Ph.D.

PROFESSOR, FACULTY OF MEDICINE, AND DIRECTOR OF THE INTERNATIONAL INSTITUTE FOR INTEGRATIVE SLEEP MEDICINE, UNIVERSITY OF TSUKUBA; ADJUNCT PROFESSOR IN MOLECULAR GENETICS, UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER

Dr. Yanagisawa is a Professor in the Faculty of Medicine and Director of the International Institute for Integrative Sleep Medicine at the University of Tsukuba in Japan. He is also an Adjunct Professor in the Department of Molecular Genetics at the University of Texas Southwestern Medical Center. His laboratory focuses on identifying and genetically characterizing the physiological functions of novel neuropeptides, such as endothelins and orexins. These neuropeptides are involved in the regulation of life-sustaining processes such as circulation, feeding, and sleep. Dr. Yanagisawa’s team discovered orexin-A and orexin-B, which play a role in arousal and wakening and may also be involved in the regulation of feeding behavior. Studies in his laboratory have shown a clear link between orexin deficiency and narcolepsy.

Dr. Yanagisawa is a former Investigator of the Howard Hughes Medical Institute. He also has received numerous awards, including election to the National Academy of Sciences. Dr. Yanagisawa received his M.D. and Ph.D. in pharmacology from the University of Tsukuba in Japan.

Investors

Bay City Capital

Bay City Capital is a life sciences venture capital firm investing in opportunities across the various life sciences sectors in companies at all stages of development.  Established in 1997, the firm has managed five venture capital funds representing over $1.3 billion in capital commitments.  Bay City Capital has invested in over 100 life sciences companies globally, including Epizyme, Epocrates, GenturaDx, Hyperion Therapeutics, Idev Technologies, Ion Torrent Systems, Lexicon, MAP Pharmaceuticals, Medarex, Nabsys, NextWave Pharmaceuticals, Oculex Pharmaceuticals, Pharmion, Reliant Pharmaceuticals, and Sunesis Pharmaceuticals.  For more information, visit www.baycitycapital.com.

We're Committed to Improving the Health of Millions of people. Join Us.

Reset is an equal opportunity employer that offers competitive compensation and benefits. Join the Reset team and become part of a fast-paced, cutting edge organization committed to scientific excellence and dedicated to improving the health of millions of people. We strive to create an environment that fosters creativity and teamwork while providing opportunities for personal and professional growth.

CAREERS

Click here to see our open positions.

Send your resume to careers@resettherapeutics.com.

Contact Us

Reset Therapeutics, Inc.
260 Littlefield Avenue, Suite 200
South San Francisco, CA 94080
650.235.4150
info@resettherapeutics.com